Your data on MRCVSonline
The nature of the services provided by Vision Media means that we might obtain certain information about you.
Please read our Data Protection and Privacy Policy for details.

In addition, (with your consent) some parts of our website may store a 'cookie' in your browser for the purposes of
functionality or performance monitoring.
Click here to manage your settings.
If you would like to forward this story on to a friend, simply fill in the form below and click send.

Your friend's email:
Your email:
Your name:
 
 
Send Cancel

First liquid solution for hypertension in cats
Semintra will be launched in a number of EU countries during September 2018.

Easy-to-give solution for pet owners and vets

The first liquid solution for feline hypertension has been launched by Boehringer Ingelheim.

In a press release, Boehringer Ingelheim said that Semintra 10 mg/ml Oral Solution ‘provides a new, well-accepted and easy-to-give liquid formulation, making management of feline hypertension easier for cat owners and veterinarians’.

“We are proud to continue to set new standards of care for cats to optimise their health and well-being through the veterinarian,” said Shawn Hooker, global head of strategic business unit pet vet at Boehringer Ingelheim.

“Early disease detection and early treatment are key to ensure cats live longer and happier lives. With Semintra we offer a pet owner-friendly, easy-to-give solution to help raise the quality of life of cats with hypertension while providing reliable long-term blood pressure control.”

The approval of Semintra as a veterinary medicine for the treatment of feline systemic hypertension follows marketing authorisation in the EU. It will be launched in a number of countries during September 2018.

Further information about Semintra can be found on the European Medicines Agency website.

Become a member or log in to add this story to your CPD history

FIVP launches CMA remedies survey

News Story 1
 FIVP has shared a survey, inviting those working in independent practice to share their views on the CMA's proposed remedies.

The Impact Assessment will help inform the group's response to the CMA, as it prepares to submit further evidence to the Inquiry Group. FIVP will also be attending a hearing in November.

Data will be anonymised and used solely for FIVP's response to the CMA. The survey will close on Friday, 31 October 2025. 

Click here for more...
News Shorts
CMA to host webinar exploring provisional decisions

The Competition and Markets Authority (CMA) is to host a webinar for veterinary professionals to explain the details of its provisional decisions, released on 15 October 2025.

The webinar will take place on Wednesday, 29 October 2025 from 1.00pm to 2.00pm.

Officials will discuss the changes which those in practice may need to make if the provisional remedies go ahead. They will also share what happens next with the investigation.

The CMA will be answering questions from the main parties of the investigation, as well as other questions submitted ahead of the webinar.

Attendees can register here before Wednesday, 29 October at 11am. Questions must be submitted before 10am on 27 October.

A recording of the webinar will be accessible after the event.